TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment, has announced its participation in two upcoming investor conferences: 1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment, has announced its participation in two upcoming investor conferences:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5, 2024, at 8:30 a.m. ET at the New York Marriott Marquis.
2. H.C. Wainwright 26th Annual Global Investment Conference: Presentation on September 10, 2024, at 9:00 a.m. ET at the Lotte New York Palace Hotel.
Webcasts of both events will be available on TScan's website under the "Events and Presentations" section, with archived replays accessible for 90 days post-event.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was -0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference; the fireside chat will be held at the New York Marriott Marquis on Thursday, September 5, 2024 at 8:30 a.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Tuesday, September 10, 2024 at 9:00 a.m. ET
Webcasts of the fireside chat and presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcasts will be available on the Company’s website for 90 days following the events.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA Phase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.